Site-directed mutagenesis of class I HLA genes. Role of glycosylation in surface expression and functional recognition.
Open Access
- 1 November 1987
- journal article
- research article
- Published by Rockefeller University Press in The Journal of Experimental Medicine
- Vol. 166 (5) , 1329-1350
- https://doi.org/10.1084/jem.166.5.1329
Abstract
We have investigated the role of the carbohydrate moiety on the HLA-B7 molecule in mAb and CTL recognition using oligonucleotide-directed mutagenesis and gene transfer techniques. A conservative substitution of asparagine to glutamine at amino acid 86 in HLA-B7 was created to abolish the unique glycosylation site present on all HLA molecules. A second mutant B7 molecule was made by substituting asparagine-aspartic acid-threonine for the resident lysine-aspartic acid/lysine tripeptide at amino acids 176-178, thus creating an N-linked glycan at amino acid 176, which is additionally present on all known murine H-2 class I antigens. Upon gene transfer into mouse and human cell recipients, the HLA-B7M176+ mutant and normal HLA-B7 expressed identical levels of surface protein. However, the binding of two mAbs (MB40.2 and MB40.3) thought to recognize different epitopes of the HLA-B7 molecule was completely eliminated. In contrast, the HLA-B7M86- mutant displayed no surface expression (mouse L cells) or minimal surface expression (human RD cells or mouse L cells coexpressing human beta 2 microglobulin [beta 2m]) after indirect immunofluorescence (IIF) and flow cytometric analysis with a panel of 12 HLA-B7 mAb reactive with monomorphic and polymorphic determinants. Immunoprecipitation analysis demonstrated that intracellular denatured mutant protein was present. Tunicamycin treatment did not rescue the expression of HLA-B7M86- antigens to the cell surface; while interferon did induce higher levels of surface expression. Tunicamycin treatment also did not allow binding of the mAbs MB40.2 or MB40.3 to HLA-B7M176+ mutant antigens, suggesting that the carbohydrate moiety itself was not directly involved in the recognition or conformation of these mAb epitopes. Further mutation of the B7M86- molecule to create a glycan moiety at amino acid position 176 (B7M86-/176+) did not rescue normal levels of surface expression. Finally, neither mutation was seen to affect recognition by a panel of 12 allospecific CTL clones. The low expression of HLA-B7M86- on the surface of human cell transfectants was sufficient to achieve lysis, albeit at a reduced efficiency, and lysis could be increased by interferon induction of higher levels of expression. Thus, the carbohydrate moiety on HLA antigens plays a minimal or nonexistent role in recognition by available mAb and allospecific CTL clones.This publication has 46 references indexed in Scilit:
- Detection of specific sequences among DNA fragments separated by gel electrophoresisPublished by Elsevier ,2006
- Expression and function of a nonglycosylated major histocompatibility class I antigen.The Journal of Experimental Medicine, 1986
- Further studies on the epitopes of HLA-B7 defined by murine monoclonal antibodiesHuman Immunology, 1986
- Carbohydrate moieties of major histocompatibility complex class I alloantigens are not required for their recognition by T lymphocytes.The Journal of Experimental Medicine, 1985
- Dissection of serological and cytolytic T lymphocyte epitopes on murine major histocompatibility antigens by a recombinant H-2 gene separating the first two external domains.The Journal of Experimental Medicine, 1984
- Structural and genetic analyses of HLA class I molecules using monoclonal xenoantibodiesTissue Antigens, 1983
- HLA monoclonal antibody registry: a proposalTissue Antigens, 1982
- Inhibition of T cell‐mediated cytolysis by 2‐deoxy‐D‐glucose: dissociation of the inhibitory effect from glycoprotein synthesisEuropean Journal of Immunology, 1979
- Lymphocyte-mediated cytolysis of allogeneic tumor cells in vitro: III. Enzyme sensitivity of target cell antigensCellular Immunology, 1975
- Modification of in vitro immune lymphocyte-target cell interaction by some biologically active drugsImmunochemistry, 1973